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Prevention of infectious diseases in the elderly is essential to establish healthy ageing. Yet, 
immunological ageing impairs successful vaccination of the elderly. Predictive biomarkers 
for vaccine responsiveness in middle-aged adults may help to identify responders and 
non-responders before reaching old age. Therefore, we aimed to determine biomarkers 
associated with low and high responsiveness towards a primary vaccination in middle-aged 
adults, for which a tetravalent meningococcal vaccine was used as a model. 
Middle-aged adults (50-65 years of age, N=100), receiving a tetravalent meningococcal 
vaccination, were divided into low and high responders using the functional antibody 
titers at 28 days post-vaccination. A total of 48 parameters, including absolute numbers 
of immune cells and serum levels of cytokines and biochemical markers, were determined 
pre-vaccination in all participants. Heat maps and multivariate redundancy analysis (RDA) 
were used to reveal immune phenotype characteristics and associations of the low and 
high responders.  
Several significant differences in pre-vaccination immune markers were observed between 
the low and high vaccine responders. Moreover, RDA analysis revealed a significant 
association between the pre-vaccination immune phenotype and vaccine responsiveness. 
In particular, our analysis pointed at high numbers of CD4 T-cells, especially naïve CD4 and 
Treg subsets, to be associated with low vaccine responsiveness. In addition, low responders 
showed lower pre-vaccination IL-1Ra levels than high responders. 
This explorative biomarker study shows associations between the pre-vaccination immune 
phenotype and vaccine responsiveness after a primary meningococcal vaccination in 
middle-aged adults. Consequently, these results provide a basis for predictive biomarker 
discovery for vaccine responsiveness that will require validation in larger cohort studies. 
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Introduction 
Prevention of infectious diseases in the elderly is essential to establish healthy ageing in 
the rapidly growing ageing population. Yet, immunological ageing impairs successful 
vaccination in the elderly [1-3]. Timely vaccination of middle-aged adults may be an 
alternative option to strengthen the memory immunity before reaching old age. Previously, 
we showed that a primary meningococcal vaccination, containing antigens towards which 
no or very low pre-vaccination immunity exists, was highly immunogenic in middle-aged 
adults [4]. Current research focusses on the identification of immune markers in older 
individuals to be able to predict the vaccine responders and non-responders [5, 6]. At 
present, the discovery of these predictive immune markers at advanced age is challenging 
and results are not unambiguous. 
Potential biomarkers for vaccine responsiveness may relate to shifts in the immune 
phenotype from naïve to more memory cells during ageing. This phenomenon occurs 
especially in the T-cell compartment and is caused by thymus involution [7-12]. Accordingly, 
the responsiveness to a yellow fever vaccine was found positively associated with the 
numbers of circulating naïve CD4 T-cells that had recently left the thymus [13]. Infection 
with persistent viruses, such as cytomegalovirus (CMV), enhances the numbers of late-
differentiated T-cells and consequently may accelerate immunological ageing [14, 15]. 
High numbers of these late-differentiated T-cells were negatively associated with influenza 
and varicella zoster (VZV) vaccine responses [16, 17]. In addition, increased numbers of 
regulatory T-cells (Tregs) are observed at old age [18, 19] which may underlie the lower 
responsiveness to the influenza and VZV vaccinations [17, 20]. 
Age-associated changes in the B-cell compartment have also been reported and include 
a decrease in naïve B-cells and a subsequent increase in late-differentiated and exhausted 
B-cells, as well as B-cells with inflammatory characteristics [21-23]. Several vaccination studies 
described a positive correlation between the frequencies of pre-vaccination Ig switched 
memory B-cells and the responsiveness to influenza and hepatitis B vaccines [16, 22, 24-
26], whereas, late/exhausted (CD27-IgD-) memory B-cells were negatively correlated with 
the response to the influenza vaccine [22]. Moreover, B-cell expression levels of activation-
induced cytidine deaminase (AID) and TFN-α after in vitro stimulation were found predictive 
for humoral responses after influenza vaccination [22, 25, 27-29]. 
In addition, several innate immune functions, gene signatures, or miRNA expressions were 
associated with influenza vaccine responsiveness [24, 30, 31]. Moreover, the age associated 
increase in inflammatory mediators, also known as ‘inflammageing’ [32-35], as well as 
modified expression of biochemical markers, such as dehydroepiandosterone sulphate 
(DHEAs) [36] and vitamin D [37], might affect the immune function at advancing age [38]. 
Also, a range of vaccination responses, for example to diphtheria, tetanus and influenza, are 
substantially influenced by vaccine specific pre-vaccination immunity [26, 30]. 
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The studies mentioned provide some promising predictive biomarkers that require 
validation in other cohort studies. Correspondingly, in this study we aimed to explore 
differences in the pre-vaccination immune phenotype between low and high vaccine 




Data from 100 middle-aged (50-65 years of age, 50% males) adults who received the 
tetravalent meningococcal vaccine conjugated to tetanus toxoid was used in this 
explorative biomarker study. These participants were included in a larger cohort study, 
of which exclusion criteria and study procedures are described elsewhere [4]. In short, 
pre-vaccination blood samples were drawn from all participants as well as 28 days, and 1 
year post-vaccination blood samples. Serum samples were collected at the different time 
points using serum clotting tubes (BD Biosciences) and were immediately kept cold and 
stored within 4 hours in aliquots at -20°C and -80°C before further use. Blood samples were 
collected in tubes containing lithium heparin (BD Biosciences) for detailed cellular immune 
phenotyping prior to vaccination. Subsequently, different immune parameters, i.e. absolute 
immune cell counts, serum cytokines, CMV specific antibodies, and biochemical markers 
were measured in the pre-vaccination blood samples of these participants. Meningococcal 
specific functional antibody titers were measured in the pre-vaccination, as well as 28 days 
and 1 year post-vaccination samples. A schematic overview of the study outline is depicted 
in Figure 1. In addition, all participants filled in a short health questionnaire. 
Figure 1. Study outline
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Participant selection
Functional antibody titers for the 3 different meningococcal groups (Meningococci C, W, 
and Y) were measured with the serum bactericidal antibody assay in 100 middle-aged 
adults, as previously described [4, 39, 40]. Meningococci A specific analysis was left out, due 
to interference of cross-reactive antibodies in the antibody assays. A functional antibody 
titer of 8 was considered to be protective, whereas a functional antibody titer of 128 was 
applied as a more conservative long-term correlate of protection [4, 39]. 
The quartiles of the functional antibody titers 28 days post-vaccination were calculated. 
Participants with a functional antibody titer matching the corresponding titer of the first 
quartile or below were considered low responders, whereas those matching the titer of 
the 3rd quartile or above were considered high responders. Since part of the participants 
showed antibody titers equal to the cut-off value, the lowest and highest quartile do not 
include 25 % of the participants. In total, 25, 46, and 40 low responders and 27, 35, and 34 
high responders were defined for MenC, MenW, and MenY, respectively. 
Flow cytometric analysis
At the pre-vaccination time point the absolute numbers of a broad range of immune cell 
subsets were determined as described previously [41-43]. In brief, the absolute numbers 
of lymphocytes, T-cells, B-cells, NK-cells, monocytes, and granulocytes were measured 
in fresh whole blood samples (within 18 hours after collection) using TruCOUNT tubes. 
Gating strategies as well as a detailed description of the antibodies used were as published 
previously [41]. An overview of the phenotype definitions of the different cellular subsets 
measured is depicted in S. Table 1. These absolute cell numbers were also used to calculate 
the ratios between the (memory) Treg cells and the CD4+CD45RO+ effector memory T 
(TemRO) cells as well as between the CD4 naïve or CD4+CD45RA+CD25dim cells and the 
CD4 memory cells. The CD4 memory cells were defined as the sum of the CD4 central 
memory (CM), CD4 TemRO, and CD4+CD45RA+ effector memory T (TemRA) cells. 
Serum cytokines 
A set of inflammatory (TNF-α, MCP-1, soluble CD40L, and IL-6) and one anti-inflammatory 
(IL1 receptor antagonist (IL-1Ra)) serum cytokines were measured in serum samples that 
were kept cool right after harvest and stored at -80 within 4 hours and prevented from 
freeze-thaw cycles. Multiplex immunoassays (MIA) were used to measure the serum cytokine 
levels as described previously [44, 45]. Since serum levels of IL-6 were below detection limit, 
IL-6 was left out of the analysis. 
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Serum biochemical parameters 
Serum levels of C-reactive protein (CRP; mg/L), Rheumatoid factor (RF; IU/mL), Reactive 
Oxygen Metabolites (ROM; IU/L), and Total Thiol (TTT; μmol/L) were measured with a clinical 
auto-analyzer (Dx5, Beckman-Coulter). Dehydroepiandrosterone Sulphate (DHEAs; μmol/L) 
and 25-Hydroxy-Vitamin-D (VitD; nmol/L) were measured using the immuno-analyser 
Acces-2 from Beckman Counter. 
Statistical analyses 
The functional antibody titers were compared between the high and low responders with 
the Mann Whitney U test. The geometric means with the 95% confidence intervals (CI) are 
indicated in the graphs. The Chi-square test was used to determine significant differences 
in patient characteristics between the high and low vaccine responders. 
The different immune markers were compared between the high and low responders 
using the Mann Whitney U test. Furthermore, the group specific geometric mean values 
of the different immune markers were normalized to z-scores using the geometric means 
and standard deviation of the total group of 100 participants. The normalized z-scores were 
displayed on a color scale in the heat maps, ranging from red (below the geometric mean of 
the total group) to blue (above the geometric mean of the total group). The color darkness 
is representative of the deviation from the total group geometric mean. For these analyses, 
SPSS V22.0 and Graphpad Prism V7 were used. 
Multivariate redundancy analysis (RDA) was used to asses associations between vaccine 
responsiveness and the pre-vaccination immune phenotype. The absolute numbers 
of immune cells, as well as the levels of serum cytokines and biochemical markers were 
imported in the analysis as biological variables, whereas vaccine responsiveness, age, sex, 
and CMV were included as explanatory variables. Significance of the explanatory variables 
was assessed by Monte Carlo permutation testing (MCPT). The p-values as well as the False 
Discovery Rates (FDR) are given.  Biological variables with the highest variation explained 
by the explanatory variables are depicted in the plots (FitE >15). Canoco5 software 
for Windows [46] was used to perform this analysis. A p-value of < 0.05 was considered 
statistically significant.
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Results 
Participant characteristics 
The functional antibody titers of the low and high vaccine responders 28 days post-
vaccination are depicted in Figure 2a. Although the low responders possess a functional 
antibody titer below or matching the first quartile of that of the total group, most of these 
values were above the protection level (functional antibody titer of 8). The fold differences 
in functional antibody titers between the low and high vaccine responders at 28 days post-
vaccination is 141.5, 15.2, and 16.7, for MenC, MenW, and MenY respectively. No difference in 
pre-vaccination functional antibody titers was found between the low and high responders 
(Figure 2b). The functional antibody titers of part of the low vaccine responders had 
declined below the protection level at 1 year post-vaccination, whereas all high responders 
were still highly protected (Figure 2c). 
Participant characteristics were compared between the low and high vaccine responders 
(Table 1). Only for MenC, the low responders were significantly older as compared to the 
high responders. Sex distribution, the number of CMV seropositive participants and BMI were 
comparable between the low and high responders. Moreover, no significant differences 
in disease incidence (within the last year), medication use (within the last 6 months), the 
incidence of recent infections (within the last 4 weeks), smoking or physical activity were 
observed. Not all participants were identified as low or high responder consistently for all 
meningococcal groups. 
Differences in pre-vaccination immune markers between high and low 
vaccine responders
At first, the absolute numbers of immune cells were compared between the high and low 
responders for the different meningococcal groups separately (Figure 3a). Low responders 
to MenC possessed significantly higher absolute numbers of naïve Treg (p=0.033), 
CD45RA+CD25dim (p=0.005), CD4 naïve (p=0.021), CD4 TemRA early (p=0.024) and CD8 CM 
(p=0.038) cells as compared to the high responders (Figure 3a and S. Figure 1a,c,d,f,g). 
Moreover, trends towards higher absolute numbers of memory Treg (p=0.084) and CD4 
TemRA (p=0.057) cells were found in the low responders (Figure 3a and S. Figure 2b and 
e). In addition, the low responders to MenC showed lower serum levels of IL-1Ra (p=0.035) 
as compared to the high responders (Figure 3b and S. Figure 1h and i), as well as a trend 
towards lower VitD levels (p=0.075) (Figure 3b and S. Figure 2j). 
Low responders for MenW possessed significantly higher absolute numbers of memory 
Treg cells (p=0.039) (Figure 3a and S. Figure 2a) as well as a trend towards lower levels of 
IL-1Ra (p=0.057) (Figure 3b and S. Figure 2b) as compared to the high responders. 
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Males (%) 13 (52%) 16 (59%) 21 (45.6%) 19 (54.3%) 20 (50%) 17 (50%)














Disease in last year (number, %)
Diabetes type II 0 (0%) 1 (3.7%) 2 (4.3%) 3 (8.6%) 1 (2.5%) 2 (5.9%)
High blood pressure 5 (20.0%) 3 (11.1%) 8 (17.4%) 5 (14.3%) 6 (15%) 8 (23.5%)
Vascular diseases 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2.5%) 0 (0%)
Lung diseases 1 (4.0%) 1 (3.7%) 0 (0%) 4 (11.4%) 2 (5%) 2 (5.9%)
Rheumatic diseases 1 (4.0%) 1 (3.7%) 2 (4.3%) 0 (0%) 2 (5%) 0 (0%)
Gastro-intestinal diseases 0 (0%) 2 (7.4%) 2 (4.3%) 1 (2.9%) 2 (5%) 2 (5.9%)
Other diseases 1 (4.0%) 1 (3.7%) 1 (2.2%) 3 (8.6%) 1 (2.5%) 3 (8.8%)
No serious disease 18 (72%) 19 (70.4%) 35 (76.1%) 26 (74.3%) 31 (77.5%) 24 (70.6%)
Medication last 6 months (number, %)
Medication for infection # 0 (0%)  4 (14.8%) 3 (6.5%) 4 (11.4%) 2 (5%) 2 (5.9%)
Cholesterol lowering medication 2 (8.0%) 2 (7.4%) 5 (10.9%) 5 (14.3%) 3 (7.5%) 4 (11.8%)
Diabetic medication 0 (0%) 1 (3.7%) 1 (2.2%) 3 (8.6%) 0 (0%) 2 (5.9%)
Blood pressure lowering 
medication
7 (28.0%) 3 (11.1%) 9 (19.6%) 6 (17.1%) 7 (17.5%) 8 (23.5%)
Immunosuppressive medication 0 (0%) 1 (3.7%) 1 (2.2%) 2 (5.7%) 1 (2.5%) 1 (2.9%)
No medication 18 (72%) 19 (70.4%) 32 (69.6%) 23 (65.7%) 30 (75%) 23 (67.6%)
Infections (number, %)
Influenza < 4 weeks 0 (0%) 1 (3.7%) 1 (2.2%) 0 (0%) 1 (2.5%) 0 (0%)
Cold < 4 weeks 6 (24.0%) 3 (11.1%) 7 (15.2%) 10 (28.6%) 7 (17.5%) 6 (17.6%)
No infection <4 weeks 19 (76.0%) 25 (92.6%) 39 (85.8%) 26 (74.3%) 33 (82.5%) 29 (85.3%)
Smoking (number, %)
Cigarette smoking 6 (24.0%) 3 (11.1%) 6 (13%) 3 (8.6%) 6 (15%) 4 (11.8%)
Cigars, pipe smoking 1 (4.0%) 0 (0%) 3 (6.5%) 1 (2.9%) 3 (7.5%) 1 (2.9%)
No smoking 18 (72%) 25 (92.6%) 38 (82.6%) 32 (91.4%) 32 (80%) 30 (88.2%)
Physical activity (number, %)
Weekly or more 17 (68.0%) 19 (70.4%) 31 (67.4%) 24 (68.6%) 27 (67.5%) 25 (73.5%)
Less than weekly 4 (16.0%) 2 (7.4%) 8 (17.4%) 4 (11.4%) 6 (15%) 4 (11.8%)
No activity 4 (16.0%) 7 (25.9%) 7 (15.2%) 8 (22.9%) 7 (17.5%) 6 (17.6%)
# Medication used more than 3 months ago and mainly consisting of corticosteroids and antibiotics. 
*p<0.05, significant differences are depicted in bold and underlined. The Chi-square test was used to determine statistical 
significances. 
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Finally, the low responders for MenY had significantly higher absolute numbers of 
CD45RA+CD25dim cells (p=0.022) as well as lower absolute numbers of natural effector 
(CD27+IgD+) B-cells (p=0.008), T-cells (p=0.043), CD4 TemRO intermediate cells (p=0.011), 
CD8 TemRO cells (p=0.027), and CD8 TemRO late cells (p= 0.036) than the high responders 
(Figure 3a and S. Figure 3e,b,d,h,i,and k). Moreover, trends towards lower absolute 
numbers of total B-cells (p=0.060), CD27+ memory B-cells (Bmem)(p=0.062), CD4RO T-cells 
(p=0.070), CD4RO early T-cells (p=0.081), and CD8 TemRO intermediate T-cells (p=0.090) 
(Figure 3a and S. Figure 3a, c, f, g, and j) as well as a trend to a lower BMI (p=0.053) 
























Figure 3. Comparison of pre-vaccination immune markers between the high and low vaccine 
responders.  
Heat maps comparing the absolute immune cells numbers (a), serum cytokines and biochemical markers (b) 
between the low and high vaccine responders for the different meningococcal serotypes separately. The absolute 
immune cell numbers as well as the concentrations of the serum markers were normalized to z-scores using the 
geometric means. The geometric means of the two groups were compared with the overall group geometric 
mean and standard deviation. The normalized z-scores are displayed on a colour scale, ranging from red (below 
the geometric mean of the total group) to blue (above the geometric mean of the total group). The white colour 
indicates values that are equal to the group geometric mean. The stronger the deviation from the group geometric 
mean, the darker the colour. The different immune markers were compared between the low and high responders 
using the Mann Whitney U test. # p<0.1, * p<0.05, ** p<0.01. MenC: low N=25, high N=27; MenW: low N=46, high 
N=35; and MenY: low N= 40, high N= 34. 
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Multivariate redundancy analysis (RDA) revealed significant associations 
between the pre-vaccination immune phenotype and vaccine responsiveness 
In order to determine whether high or low vaccine responsiveness at day 28 post-vaccination 
was significantly associated with all measured pre-vaccination immune markers combined, 
hereafter called the immune phenotype; a multivariate RDA was performed for the three 
meningococcal groups separately (Figure 4a-c). Overall the included variables (age, sex, 
CMV, BMI, and vaccine response) explained 14.5%, 10.4%, and 12.0% of the total variation in 
immune phenotype for MenC, MenW, and MenY respectively. 
For MenC and MenY, the variable ‘vaccine response’ was significantly associated with the 
immune phenotype (MenC: p=0.012, FDR= 0.07 and MenY: p= 0.028, FDR= 0.098) (Figure 
4a and c). As expected, based on the heatmap depicted in Figure 3a, for MenW no 
significant association between vaccine response and immune phenotype was observed 
(p=0.068, FDR= 0.16) (Figure 4b). 
For the MenC group higher levels of DHEA, TTT, and ROM as well as higher absolute numbers 
of memory Treg cells, naïve Treg cells, CD45RA+CD25dim cells, CD4 TemRA early cells, CD4 
naïve cells, lymphocytes, and CD4 T-cells were strongly associated with low responsiveness, 
whereas higher levels of IL-1Ra were related with high responsiveness (Figure 4a). For MenY, 
higher levels of DHEA and higher absolute numbers of CD4 naïve, CD45RA+CD25dim, CD8 
naïve and naïve Treg cells were strongly associated with low vaccine responsiveness, while 
high absolute numbers of Bmem cells were linked to high vaccine responsiveness (Figure 4c).
In addition, CMV seropositivity was significantly associated with the immune phenotype 
(Figure 4a: p=0.098, FDR= 0.23, Figure 4b, p=0.002, FDR= 0.014, and Figure 4c, p=0.002, 
FDR= 0.014). In these analyses, CMV seropositivity was associated with higher absolute 
numbers of CD4RO late, CD4RA late, and CD8RA late T-cells, and not related to either low or 
high vaccine responsiveness. Of note, the explanatory variables BMI, age, and sex were not 
significantly associated with the immune phenotype. 
Differences in immune cell ratios in the CD4 T-cell compartment between the 
high and low vaccine responders
In relation to the mentioned findings of higher naïve CD4 T-cells and memory Treg cells 
in the low vaccine responders, we determined whether the ratio of naïve to memory cells, 
as well as the ratio of Treg to effector cells in the CD4 T-cell compartment was different 
between the low and high vaccine responders (Figure 5). No difference in the ratio 
between the total Treg cells and the number of CD4 TemRO T-cells was observed (Figure 
5a), whereas the ratio of memory Treg cells to CD4 TemRO T-cells was significantly higher 
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In addition, the low responders for MenC and MenY possessed a significantly higher ratio of 
the naïve CD4 T-cells and the total CD4 memory cells (Figure 5c), as well as a higher ratio 
of the post thymically expanded CD45RA+CD25dim cells and the total CD4 memory cells 
(Figure 5d). Thus, the higher numbers of both naïve CD4 T-cell subsets and Tregs as seen 
in low responders at baseline (pre-vaccination) gives rise to clear compositional changes in 
the peripheral CD4 T-cell compartment.
Figure 5. Comparison of immune cell ratios in the CD4 T-cell compartment between the high 
and low vaccine responders. 
Comparison of the Treg/TemRO ratio (a), memory Treg/TemRO ratio (b), CD4 naïve/ CD4 memory ratio (c), and 
CD45RA+CD25dim/ CD4 memory ratio (d) between the low (red) and high (blue) vaccine responders for the 
different meningococcal groups separately. The total CD4 memory cells were determined as the sum of the CD4 
CM, CD4 TemRO, and CD4 TemRA cells. The low and high responders were compared with the Mann Whitney U 




In this explorative study, we investigated whether the pre-vaccination immune phenotype 
was significantly different between the middle-aged adults being either low or high 
responder after a primary meningococcal vaccination. Interestingly, the numbers of several 
CD4 T-cell subsets differed between the low and high vaccine responders. More specifically, 
low vaccine responders possessed higher numbers of naïve Treg, memory Treg, naïve CD4 
cells, and the subset of post thymically expanded CD4+CD45RA+CD25dim T-cells, whereas 
high responders showed high levels of serum IL-1Ra. These results suggest that the pre-
vaccination CD4 signature may be used to identify middle-aged adults who are potential 
non/low responders to a primary meningococcal vaccine. Identification of these middle-
aged adults may help improve timely vaccination strategies, since vaccination schemes, 
doses, and adjuvant use might be adapted to improve the vaccine responsiveness in these 
adults.  
Numbers of Treg cells are known to increase with advancing age and suggest elevated 
immune suppression in older adults, although the exact functionality of these Treg cells in 
ageing individuals is still under investigation [18, 47]. Accordingly, high numbers of Tregs 
were previously associated with low VZV vaccine responses in nursing home elderly [17]. 
Within our study, high absolute numbers of both naïve and memory Tregs were associated 
with low vaccine responsiveness. Naïve Treg cells express CCR7 enabling these cells to 
migrate to lymphoid organs, whereas memory Tregs home to the sites of inflammation 
along with effector T-cells [48, 49]. Accordingly, our results suggest enhanced suppression 
of the vaccine response both in the lymphoid organs as well as the site of vaccination in low 
responders. Elevated numbers of Treg cells might suppress T-cell responses towards the 
tetanus carrier in this conjugated meningococcal vaccine and/or inhibit B-cell responses 
directly [50]. Our results confirm previous findings of high numbers of memory Treg cells in 
low vaccine responders to influenza [20], whereas we are the first showing an association 
between low vaccine responsiveness and high numbers of naïve Tregs. Of importance, 
we observed a higher ratio of memory Treg to effector CD4 T-cells in the low responders, 
suggesting a shift in the Treg/Teffector balance, as previously observed with advancing age 
[20]. 
The consistent association found between high numbers of CD4 naïve and the post 
thymically expanded CD4+CD45RA+CD25dim cells and a higher ratio of these naïve cells to 
the memory CD4 T-cell compartment with low vaccine responsiveness was unexpected, 
since a naïve T-cell repertoire is generally accepted to be beneficial in older adults [8, 10]. 
Previously, the CD4+CD45RA+CD25dim subset was found to represent a broad and functional 
reservoir of naïve CD4 T-cells, although some contraction in certain TCR Vβ families was 
observed in comparison to naïve CD4 T-cells that recently left the thymus [51]. Since no 
prior studies were available that linked the numbers of CD4+CD45RA+CD25dim cells to 
7159
An explorative biomarkers study for vaccine responsiveness
vaccine responses, our findings indicate the necessity for further research into repertoire 
size and functionality of these cells. However, the increase in memory Treg cells might be 
the dominant factor in predicting vaccine response, overruling the presence of a capable 
naïve CD4 T-cell repertoire. 
In line with the different studies investigating biomarkers for influenza and hepatitis B 
vaccine responses in the elderly [16, 22, 24], we observed trends towards lower numbers 
of switched memory CD27+ B-cells in the low responders. In contrast, we did not find 
increased numbers of CD27- memory B-cells in the low responders, as reported by others 
in vaccine recipients above 65 years of age [22]. In addition, low numbers of natural effector 
CD27+IgD+ B-cells, cells that were previously found to decrease with age [23], were 
observed in the low vaccine responders. Since we  previously described that IgM is essential 
in the antibody functionality against the meningococcal groups [4], lower numbers of these 
natural effector cells, mainly producing IgM, likely explain the lower functional antibody 
titers. 
Currently, effects of latent CMV infection on vaccine responses is controversial [52]. Despite 
the clear associations between CMV seropositivity and higher numbers of late differentiated 
T-cells, we did not find an association between CMV seropositivity and meningococcal 
vaccine responsiveness. As this meningococcal vaccine response is primarily B-cell 
mediated, the effect of CMV might be limited. Hence, the effects of CMV on T-cell mediated 
vaccine responses, i.e. to influenza and VZV vaccination should be further elucidated. 
Although frequently suggested by others [53-56], we did not observe any effects of sex and 
BMI on the vaccine responses. Moreover, the effect of chronological age was inconsistent, 
although low responders to MenC were significantly older than high responders. 
Of note, high levels of IL-1Ra were found in the high responders. IL-1Ra is known as the 
receptor antagonist of the IL-1 family, executing anti-inflammatory functions [57, 58]. 
These results possibly suggest that IL-1Ra acts as an anti-inflammatory counterpart of the 
‘inflammageing’ process. Of note, a trend towards high levels of MCP-1 was found in the low 
responders. MCP-1 is classified as a pro-inflammatory cytokine, attracting monocytes to the 
site of inflammation, and serum levels were shown to increase with age [59]. Consequently, 
our findings may suggest a higher pro-inflammatory state in the low responders [32, 33]. 
Nevertheless, serum levels of other inflammatory cytokines, such as IL-6 and TFN-α were still 
low in all participants. 
Of importance, associations with the immune phenotype were primarily found between 
the extremes in the vaccine response, being either low or high responders. The 
intermediate group showed high variability of immune markers. In addition, our results may 
imply meningococcal group specific associations between the pre-vaccination immune 
phenotype and vaccine responsiveness. Noteworthy, the difference in functional antibody 
titers between the low and high vaccine responders was largest for MenC, possibly explaining 
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the higher numbers of immune parameters found associated with the vaccine response for 
this meningococcal group. Moreover, the participants that were classified as low or high 
responder did not completely overlap between the different meningococcal groups. This 
might be explained by the structural differences in the meningococcal polysaccharides by 
which different epitopes will induce distinct immune responses [60], also shown previously 
for several pneumococcal conjugated polysaccharides [61]. Furthermore despite similar pre-
vaccination functional antibody titers in the low and high vaccine responders, differences in 
numbers of meningococcal group-specific memory B-cells in the bone marrow could have 
been present due to historical contacts [62] and affect the vaccine response. Nevertheless, 
the finding of meningococcal group specific associations between vaccine responsiveness 
and immune phenotype is remarkable and requires further research.  
An important strength of this study is the ability to compare multiple antigens and multiple 
immune parameters within the same group of participants. Also, the primary nature of the 
vaccination allowed us to explore the use of biomarkers, without the strong interference 
of pre-vaccination meningococcal immunity, as often seen in other studies. Unfortunately, 
the presence of pre-vaccination immunity in some participants did interfere with the long-
term functional antibody titers (after 1 year). Consequently, we were not able to investigate 
the associations between pre-vaccination immune phenotype and the long-term vaccine 
responsiveness, since exclusion of participants with detectable pre-vaccination functional 
antibody titers dramatically reduced the power of the statistical analysis. In addition, 
information on the genetic background of the participants could have added to the 
predictive factors in our analysis, since several studies found associations between genetic 
signatures and vaccine responsiveness [24, 30, 31]. 
Future studies, analyzing large cohorts, using different vaccines, and using similar biomarker 
analyzing techniques are warranted to validate the use of the suggested biomarkers. Hence, 
systems vaccinology, combining data on genetic background and environmental factors 
such as diet, stress and infections and even microbiome composition is a promising tool to 
discover these predictive biomarkers [63]. Moreover, future research should compare the 
suitability of biomarkers in cohorts of different ages, in order to determine the predictive 
values of these markers over the entire lifespan. 
In conclusion, our explorative biomarker analysis suggests several associations between 
the pre-vaccination immune phenotype and vaccine responsiveness after primary 
meningococcal vaccination in middle-aged adults. In general, an altered CD4 T-cell 
signature, involving high absolute numbers of naïve Treg, memory Treg, naïve CD4 T-cells 
and CD45RA+CD25dim T-cells might be used as a predictive immune phenotype for low 
vaccine responsiveness in middle-aged adults. Accordingly, these findings support the 
development of vaccination strategies to enhance the memory immunity before reaching 
old age, in the rapidly ageing population.  
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Supplementary Table 1. Phenotypical definitions of the immune cells subsets




















CD4 TemRA early SSClowCD45+CD3+CD4+CD45RO-CCR7-CD27+CD28+
CD4 TemRA intermediate SSClowCD45+CD3+CD4+CD45RO-CCR7-CD27-CD28+
CD4 TemRA late SSClowCD45+CD3+CD4+CD45RO-CCR7-CD27-CD28-
CD4 TemRO SSClowCD45+CD3+CD4+CD45RO+CCR7-
CD4 TemRO early SSClowCD45+CD3+CD4+CD45RO+CCR7-CD27+CD28+
CD4 TemRO intermediate SSClowCD45+CD3+CD4+CD45RO+CCR7-CD27-CD28+






CD8 TemRA early SSClowCD45+CD3+CD8+CD45RO-CCR7-CD27+CD28+
CD8 TemRA intermediate SSClowCD45+CD3+CD8+CD45RO-CCR7-CD27+CD28-
CD8 TemRA late SSClowCD45+CD3+CD8+CD45RO-CCR7-CD27-CD28-
CD8 TemRO SSClowCD45+CD3+CD8+CD45RO+CCR7-
CD8 TemRO early SSClowCD45+CD3+CD8+CD45RO+CCR7-CD27+CD28+
CD8 TemRO intermediate SSClowCD45+CD3+CD8+CD45RO+CCR7-CD27+CD28-
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Supplementary Figure 2. Analysis of differences in immune markers between the high and low 
responders for MenW.
The difference in absolute numbers of memory Treg (a) and levels of IL-1Ra (b) between the low (red, N= 46) and 
high (blue, N=35) responders for MenW. The geometric mean with 95% CI interval is indicated in the graphs. The 
early low and high responders were compared for the different immune markers using the Mann Whitney U test. 
Trends are given as p-values. * p<0.05.
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